Profile data is unavailable for this security.
About the company
Chengdu Easton Biopharmaceuticals Co Ltd is a China-based company mainly engaged in the research and development, production and sales of chemical raw materials and chemical pharmaceutical preparations. The Company's main products are chemical generic drugs. Its products include nalmefene hydrochloride injection, caffeine citrate injection, ibuprofen injection, bisoprolol fumarate tablets, ubenimex, etc. Its products are used in the fields of anesthesia and analgesia, cardiovascular, anti-tumor, digestion and children's medicine. The Company operates its businesses within the China market and to overseas markets such as Russia, Switzerland, Tunisia, Germany, South Korea and Japan.
- Revenue in CNY (TTM)1.31bn
- Net income in CNY249.88m
- Incorporated2009
- Employees1.40k
- LocationChengdu Easton Biopharmaceuticals Co LtdNo. 8 Ankang Road, Shuangliu DistrictCHENGDU 610219ChinaCHN
- Phone+86 2 886106668
- Fax+86 2 862321999
- Websitehttp://www.eastonpharma.cn
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Guizhou Sanli Pharmaceutical Co Ltd | 2.11bn | 328.87m | 5.79bn | 2.28k | 18.13 | 3.62 | -- | 2.74 | 0.7798 | 0.7798 | 5.05 | 3.91 | 0.8372 | 2.90 | 4.48 | 925,761.20 | 13.32 | 12.39 | 19.88 | 16.72 | 69.37 | 70.45 | 15.91 | 16.31 | 1.62 | -- | 0.2373 | 25.70 | 36.10 | 17.75 | 45.42 | 21.51 | 127.48 | -- |
| Chengdu Easton Biopharmaceuticals Co Ltd | 1.31bn | 249.88m | 6.20bn | 1.40k | 24.59 | 2.31 | -- | 4.74 | 1.43 | 1.43 | 7.47 | 15.16 | 0.3941 | 1.83 | 6.97 | 933,769.90 | 7.53 | 8.72 | 9.23 | 10.64 | 75.76 | 85.10 | 19.11 | 19.16 | 2.65 | -- | 0.0717 | 26.80 | -4.56 | 7.76 | -8.09 | 10.91 | 17.99 | -- |
| Cisen Pharmaceutical Co Ltd | 4.25bn | 529.01m | 6.45bn | 3.40k | 12.18 | 1.11 | -- | 1.52 | 1.17 | 1.17 | 9.41 | 12.89 | 0.585 | 2.15 | 6.06 | 1,250,659.00 | 7.33 | 6.94 | 9.10 | 8.56 | 57.72 | 56.27 | 12.53 | 10.77 | 2.63 | -- | 0.0329 | 33.42 | 9.75 | 3.22 | 48.92 | 0.697 | -15.19 | 10.72 |
Data as of Nov 05 2024. Currency figures normalised to Chengdu Easton Biopharmaceuticals Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
9.91%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Guotai Asset Management Co., Ltd.as of 30 Jun 2024 | 10.23m | 5.80% |
| E Fund Management Co., Ltd.as of 30 Jun 2024 | 3.43m | 1.94% |
| Chang Xin Asset Management Co., Ltd.as of 30 Jun 2024 | 1.28m | 0.72% |
| CIB Fund Management Co., Ltd.as of 30 Jun 2024 | 733.47k | 0.42% |
| Essence Fund Co., Ltd.as of 30 Jun 2024 | 486.82k | 0.28% |
| HuaAn Fund Management Co., Ltd.as of 30 Jun 2024 | 360.11k | 0.20% |
| Great Wall Fund Management Co., Ltd.as of 30 Jun 2024 | 295.21k | 0.17% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2024 | 286.73k | 0.16% |
| Bosera Asset Management Co., Ltd.as of 30 Jun 2024 | 214.72k | 0.12% |
| Fuanda Fund Management Co., Ltd.as of 30 Jun 2024 | 185.19k | 0.11% |
More ▼
Data from 30 Jun 2024 - 29 Oct 2024Source: FactSet Research Systems Inc.
